Back to resultsImpact of Sarpogrelate in the Function of Endothelial Progenitor Cells
Primary Purpose
Atherosclerosis
Status
Unknown status
Phase
Not Applicable
Locations
Japan
Study Type
Interventional
Intervention
Sarpogrelate
Sponsored by
About this trial
This is an interventional treatment trial for Atherosclerosis focused on measuring endothelial progenitor cells
Eligibility Criteria
Inclusion Criteria:
- Patients with atherosclerosis
Exclusion Criteria:
- Patients with high risk of bleeding
- Patients with pregnancy
- Patients with allergic reaction of Salpogrelate
Sites / Locations
- Aichi-Gakuin UniversityRecruiting
Outcomes
Primary Outcome Measures
The number and function of endothelial progenitor cells
Secondary Outcome Measures
Full Information
1. Study Identification
Unique Protocol Identification Number
NCT01548274
Brief Title
Impact of Sarpogrelate in the Function of Endothelial Progenitor Cells
Official Title
Impact of Sarpogrelate in the Function of Endothelial Progenitor Cells
Study Type
Interventional
2. Study Status
Record Verification Date
March 2012
Overall Recruitment Status
Unknown status
Study Start Date
October 2010 (undefined)
Primary Completion Date
October 2012 (Anticipated)
Study Completion Date
October 2012 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Aichi Gakuin University
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The purpose of this study is to evaluate the effects of Sarpogrelate in endothelial progenitor cells of patients with atherosclerosis.
Detailed Description
Endothelial progenitor cells play an important role in vasculogenesis and vascular repair. Sarpogrelate, a inhibitor of HT2A, is used an an anti-platelet drug, however, a direct effect in vascular cells is supposed.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Atherosclerosis
Keywords
endothelial progenitor cells
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)
8. Arms, Groups, and Interventions
Intervention Type
Drug
Intervention Name(s)
Sarpogrelate
Intervention Description
Sarpogrelate 300mg/day
Primary Outcome Measure Information:
Title
The number and function of endothelial progenitor cells
Time Frame
3 months
10. Eligibility
Sex
All
Minimum Age & Unit of Time
20 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Patients with atherosclerosis
Exclusion Criteria:
Patients with high risk of bleeding
Patients with pregnancy
Patients with allergic reaction of Salpogrelate
Facility Information:
Facility Name
Aichi-Gakuin University
City
Nagoya
State/Province
Aichi
ZIP/Postal Code
464-8651
Country
Japan
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Keiko Naruse, M.D., Ph.D.
Phone
+81-52-759-2111
Ext
5369
Email
narusek@dpc.agu.ac.jp
12. IPD Sharing Statement
Learn more about this trial
Impact of Sarpogrelate in the Function of Endothelial Progenitor Cells
We'll reach out to this number within 24 hrs